Compare Moderna, Inc. (MRNA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Snowflake Inc — how do they compare? Moderna, Inc. trades at $63.66 (market cap $24.18B), while Snowflake Inc trades at $334.73 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 4.8× Moderna, Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | SNOW | |
|---|---|---|
Market Cap | $24.18B | $116.01B |
Sector | Health | Technology |
52-Week High | $81.80 | $334.70 |
52-Week Low | $22.36 | $121.11 |
Enterprise Value | $20.33B | $115.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Snowflake trades at $339.00, up 1.28% with bullish technical signals and strong analyst support (81% buy ratings). The company shows impressive revenue growth from $1.2B in 2022 to $3.6B in 2025, though remains unprofitable with a -23.79% net margin. Recent earnings beats and AI platform expansions drive optimism, but premium valuation at 22.66x P/S ratio presents risk.
Outlook remains positive with AI data cloud leadership and 30% revenue growth guidance, but investors face valuation concerns and persistent losses. Key catalysts include Q2 2026 earnings on September 2nd and enterprise AI adoption trends. The stock trades near resistance at $341 with consensus price target of $302.18 suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
